IPSEN (OTCMKTS:IPSEY) Share Price Passes Above 200-Day Moving Average – Here’s Why
by Amy Steele · The Cerbat GemIPSEN (OTCMKTS:IPSEY – Get Free Report) crossed above its 200-day moving average during trading on Thursday . The stock has a 200-day moving average of $40.00 and traded as high as $48.0076. IPSEN shares last traded at $48.0076, with a volume of 205 shares trading hands.
Analyst Upgrades and Downgrades
A number of brokerages have recently commented on IPSEY. UBS Group cut IPSEN from a “strong-buy” rating to a “hold” rating in a research report on Thursday, January 8th. Deutsche Bank Aktiengesellschaft reissued a “buy” rating on shares of IPSEN in a report on Tuesday, April 14th. One equities research analyst has rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of “Hold”.
Read Our Latest Stock Report on IPSEN
IPSEN Stock Performance
The business has a fifty day moving average of $46.50 and a 200-day moving average of $40.10.
IPSEN Company Profile
Ipsen is a global biopharmaceutical company headquartered in Boulogne-Billancourt, France. Founded in 1929, the company focuses on specialty care areas including oncology, neuroscience and rare diseases. Ipsen develops, manufactures and commercializes innovative medicines that address critical unmet medical needs, offering a diverse portfolio of therapies for both adult and pediatric patient populations.
The company’s oncology franchise includes treatments for prostate, renal and hepatocellular carcinomas, with key products such as Cabometyx (cabozantinib) and Decapeptyl (triptorelin).